Methylation-Based Therapies for Colorectal Cancer
Open accessThe DOI matches its Crossref record; 236 of the 241 references it cites were found in a registry or an index.
Abstract
Colorectal carcinogenesis (CRC) is caused by the gradual long-term accumulation of both genetic and epigenetic changes. Recently, epigenetic alterations have been included in the classification of the CRC molecular subtype, and this points out their prognostic impact. As epigenetic modifications are reversible, they may represent relevant therapeutic targets. DNA methylation, catalyzed by DNA methyltransferases (DNMTs), regulates gene expression. For many years, the deregulation of DNA methylation has been considered to play a substantial part in CRC etiology and evolution. Despite considerable advances in CRC treatment, patient therapy response persists as limited, and their profit from systemic therapies are often hampered by the introduction of chemoresistance. In addition, inter-individual changes in therapy response in CRC patients can arise from their specific (epi)genetic compositions. In this review article, we summarize the options of CRC treatment based on DNA methylation status for their predictive value. This review also includes the therapy outcomes based on the patient’s methylation status in CRC patients. In addition, the current challenge of research is to develop therapeutic inhibitors of DNMT. Based on the essential role of DNA methylation in CRC development, the application of DNMT inhibitors was recently proposed for the treatment of CRC patients, especially in patients with DNA hypermethylation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, excessive demethylation by DNMT inhibitors can also disrupt normal gene expression patterns and cause toxicity [158].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [158]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ghoshal, K., Datta, J., Majumder, S., Bai, S., Kutay, H., Motiwala, T., & Jacob, S. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4727-4741.2005 · Cited by 431
RetractedPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061 · cited 1×
“and are predominantly associated with transcription start sites and promoters [7].”
BackgroundThe consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Epigenetic differences arise during the lifetime of monozygotic twins
Fraga, M. F., Ballestar, E., Paz, M. F., Ropero, S., Setien, F., Ballestar, M. L., Heine-Suñer, D., Cigudosa, J. C., Urioste, M., Benitez, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500398102 · Cited by 3,602
Nan, X., Ng, H.-H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., & Bird, A. (1998) · Nature · doi:10.1038/30764 · Cited by 3,440 · cited 1×
“The process of transcriptional repression also requires the so-called “reader” molecules, known as methyl-binding proteins (MBPs) and their corepressors, such as histone deacetylases (HDAC1 and HDAC2), Sin3A, and Mi-2 [69].”
BackgroundESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
DNA methylation: roles in mammalian development
Smith, Z. D., & Meissner, A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3354 · Cited by 3,045 · cited 1×
“DNMTs can be categorized according to their function into three groups: most abundant DNMT1, de novo DNMTs (DNMT3A and DNMT3B), and DNMT2 (with methylation activity for tRNA) [64,65].”
BackgroundOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Research works printed but not linked: 1
- Vaiserman, A.M. (2017). Epigenetics of Aging and Longevity, Academic Press. [1st ed.].
Cited by
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Fatma, H., Maurya, S. K., & Siddique, H. R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.008 · Cited by 177
Epigenetic Mechanisms of Aging and Aging-Associated Diseases
la Torre, A., Vecchio, F. L., & Greco, A. (2023) · Cells · doi:10.3390/cells12081163 · Cited by 150
“An example is represented by colorectal cancer (CRC) that often affects people over 50 years of age [85].”
BackgroundInfluentialGenetic and epigenetic dependencies in colorectal cancer development
Parmar, S., & Easwaran, H. (2022) · Gastroenterology report · doi:10.1093/gastro/goac035 · Cited by 99
Filip, S., Vymetalkova, V. P., Petera, J., Vodičková, Ľ., Kubeček, O., John, S., Čečka, F., Krupova, M., Manethová, M., Červená, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155255 · Cited by 97
Self-citationMechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“DNMT inhibitors include cytidine analogs that incorporate into DNA (e.g., azacitidine and decitabine) and non-nucleoside inhibitors that directly interact with DNMTs [158].”
DNA methylation biomarkers in colorectal cancer: Clinical applications for precision medicine
Fatemi, N., Tierling, S., Es, H. A., Varkiani, M., Mojarad, E. N., Aghdaei, H. A., Walter, J., & Totonchi, M. (2022) · International Journal of Cancer · doi:10.1002/ijc.34186 · Cited by 75
“cases of CRC develop from CIN, whereas only 10% to 15% of CRCs result from defects in the MMR system.(10)”
BackgroundWang, A., Xu, Q., Rengaowa, S., Bao, T., Xi, X., & Guo, G.-L. (2021) · Oncology Letters · doi:10.3892/ol.2021.12533 · Cited by 35
Aanniz, T., Bouyahya, A., Balahbib, A., Kadri, K. E., Khalid, A., Makeen, H. A., Alhazmi, H. A., Omari, N. E., Zaid, Y., Wong, R. S.-Y., et al. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.110907 · Cited by 30
Zhao, N., Lai, C., Wang, Y., Dai, S., & Gu, H. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189096 · Cited by 33
Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies
Imran, K., Iqbal, M. J., Ahmed, M. M., Khalid, A., Cortés, H., Reyes‐Hernández, O. D., Figueroa‐González, G., Leyva‐Gómez, G., Falzone, L., Libra, M., et al. (2025) · Medical Oncology · doi:10.1007/s12032-025-02905-z · Cited by 29
“Nonetheless, it is imperative to note that while promising, creating high-performance biomarker tools remains a work in progress [123].”
DNA Mismatch Repair Gene Variants in Sporadic Solid Cancers
Čaja, F., Vodičková, Ľ., Král, J., Vymetalkova, V. P., Naccarati, A., & Vodička, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155561 · Cited by 26
“Our recent review pointed out that promoter hMLH1 hypermethylation is associated with CIMP (CpG island methylation phenotype) and acts as main mechanism for the evolution of sporadic MSI CRC [56].”
BackgroundSelf-citationChen, P.-C., Yeh, Y., Lin, B., Chan, R., Su, P., Liu, Y.-C., Lee, C., Chen, S., & Lin, P. (2022) · Biomedicines · doi:10.3390/biomedicines10020340 · Cited by 23
“Several studies have demonstrated that DNA methylation statuses can predict the therapeutic outcomes of patients with CRC [53].”
BackgroundChatterjee, B., Ghosh, K. K., Swain, A., Nalla, K., Ravula, H., Pan, A., & Kanade, S. R. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153885 · Cited by 21
Su, M., Chang, C., Lin, C.-W., Chu, H., Tsai, T., Su, W., Chen, Y., Chang, T., Huang, C., Tsai, H., et al. (2022) · Cells · doi:10.3390/cells11030527 · Cited by 23
“In another study, aberrant DNMT expression was reported to be associated with CRC and was proposed as a potential therapeutic target [40].”
BackgroundZhai, P. C., Zhang, H., Li, Q., Yang, M. W., Guo, Y., & Xing, C. (2023) · Gene · doi:10.1016/j.gene.2023.147887 · Cited by 18
Value of methylation markers in colorectal cancer (Review)
Kong, C., & Fu, T. (2021) · Oncology Reports · doi:10.3892/or.2021.8128 · Cited by 17
“In several clinical trials, DNMTi have been used as a novel treatment for patients with CRC, particularly those with high levels of DNA methylation (118,122).”
Wang, S. S., Lewis, M., & Pitzalis, C. (2023) · Biomedicines · doi:10.3390/biomedicines11071987 · Cited by 20
“Two DNA methylation-based diagnostic biomarkers have been approved by the FDA for clinical use in the diagnosis of colorectal cancer [89] and DNA methylation at baseline has been shown to be a predictive response to therapy in colorectal cancer [89,90].”
MethodDNA hypomethylation patterns and their impact on the tumor microenvironment in colorectal cancer
Huang, H., Li, Q., Tu, X., Yu, D., Zhou, Y., Ma, L., Wei, K., Gao, Y., Zhao, G., Han, R., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00933-x · Cited by 16
“In CRC, the phenomenon of DNA hypomethylation, particularly in the context of demethylated promoters and enhancers, has gained prominence [15, 16].”
Zou, C.-S., Xie, Y., Wang, D., Liu, Y.-P., Li, M., Chen, Y., Su, Z.-L., & Liu, K.-H. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04713-9 · Cited by 13
“Recent studies have shown that DNA methylation in colorectal cancer cells can promote the proliferation, invasion, and metastasis of malignant cells [14,15] .”
BackgroundDNMT3b affects colorectal cancer development by regulating FLI1 through DNA hypermethylation
Zhou, L., Pan, L., & Fan, Y. (2023) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12647 · Cited by 14
“DNA methylation, catalyzed by DNA methyltransferases (DNMTs), controls gene expression.(12) The expression of DNMTs was reportedly elevated in various tumor tissues and cell lines, which might be one potential mechanism for the increasing methylation of promoter cytosine and guanine (CpG) islands of tumor suppressor g…”
BackgroundThe epigenetic landscape in intestinal stem cells and its deregulation in colorectal cancer
Larue, A., & Atlasi, Y. (2024) · Stem Cells · doi:10.1093/stmcls/sxae027 · Cited by 10
“108,109 Similarly, the tumor suppressor FOXD3 is repressed in CRC by promoter is hypermethylated, leading to activation of the Tuft cell-associated gene, DCLK1 , in CRC CSCs. 110,111 Similarly, E-cadherin gene CDH1 promoter is methylated in CRC, permitting Vimentin and N-cadherin upregulation that…”
BackgroundCancer stem cell marker expression and methylation status in patients with colorectal cancer
Meršaková, S., Janíková, K., Kalman, M., Marcinek, J., Grendár, M., Vojtko, M., Kyčina, R., Pindura, M., Janik, J., Mikolajčík, P., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13352 · Cited by 10
“Hypermethylated MGMT genomic regions have been previously observed in adenomas, in addition to in the non‐malignant colonic mucosa of patients with CRC, where it was found to be associated with more favorable therapeutic responses following treatment with alkylating agents (39,60).”
BackgroundInfluentialComprehensive RNA-sequencing analysis of colorectal cancer in a Korean cohort
Lee, J., Kim, J.-H., Chu, H. B. K., Oh, S., Kang, S., Lee, S., Kim, D., Oh, H., Park, J.-H., Kim, J.-S., et al. (2024) · Molecules and Cells · doi:10.1016/j.mocell.2024.100033 · Cited by 9
Epigenetics and its Therapeutic Potential in Colorectal Cancer
Oryani, M. A., Tavasoli, A., Ghalavand, M. A., Ashtiani, R. Z., Rezaee, A., Mahmoudi, R., Golvari, H., Owrangi, S., & Soleymani-Goloujeh, M. (2022) · Epigenomics · doi:10.2217/epi-2022-0067 · Cited by 10
Chen, C.-Y., Wu, J.-J., Lin, Y.-J., Hsu, C., Hu, J., Chang, P.-K., Sun, C., Yang, T., Su, J.-Q., & Chou, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810225 · Cited by 10
“Methylation of the MGMT and IFBP3 genes and the CpG island methylator’s phenotype status could be used to predict the treatment effect of 5-fluorouracil-based chemotherapy [7].”
BackgroundEpigenetic Alterations in Colitis-Associated Colorectal Cancer
Ganesh, N., Grady, W. M., & Kaz, A. M. (2026) · Epigenomes · doi:10.3390/epigenomes10010004 · Cited by 6
“Specifically, DNA methylation of inflammatory marker genes can further attenuate the development of CAC [31].”
Ray, S. K., & Mukherjee, S. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220511123104 · Cited by 7
Müller, D., & Győrffy, B. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17455 · Cited by 7
“The moderation of dysregulated methylation patterns has also been the subject of multiple trials, including the application of aspeci-fic hypomethylating agents 5-azacytidine and 2 0 -deoxy-5-azacytidine (Cervena et al., 2020).”
Targeting epigenetic modifications as an emerging immunotherapeutic strategy for cancers
Kumar, R., Jain, K., Rai, K. R., Gururajan, H., & Sarkar, K. (2025) · Immunologic Research · doi:10.1007/s12026-025-09678-7 · Cited by 7
“The presence of MLH1 methylation in CRC patients indicates a worse disease outcome [9].”
Natural Stilbenes: Their Role in Colorectal Cancer Prevention, DNA Methylation, and Therapy
Fialková, V., Ďúranová, H., Borotová, P., Klongová, L., Grabacka, M., & Speváková, I. (2024) · Nutrition and Cancer · doi:10.1080/01635581.2024.2364391 · Cited by 6
“Numerous epigenetic studies have highlighted the role of the DNA methylation machinery and the enzymes involved in this mechanism as crucial managers of DNA methylation changes in CRC pathogenesis (12).”
Fard, G. B., Amirfakhrian, R., Bafghi, M. H., & Gholamin, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04097-y · Cited by 5
“Studies have shown that the inactivation of the MLH1 gene often occurs through promoter methylation in CIMP-positive CRC patients [56].”
Liu, X., Zhu, H., Guo, B., Chen, J., Zhang, J., Wang, T., Zhang, J., Shan, W., Zou, J., Cao, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-63457-2 · Cited by 5
[Expression of DNMT3b in human bladder cancer tissue and its correlation with clinical prognosis].
Cao, Y., Xu, K., Chen, B., Wang, Y., Li, B., Li, C., & Xu, P. (2020) · PubMed · doi:10.12122/j.issn.1673-4254.2020.09.11 · Cited by 5
DNA Methylation in Cancer Epigenetics
Klupczyńska, E. A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110506 · Cited by 4
Li, C., Lu, T., Chen, H., Yu, Z., & Chen, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-59575-6 · Cited by 5
DNA methylation biomarkers for predicting lymph node metastasis in colorectal cancer
Sun, Y., Kong, D., Zhang, Q., Xiang, R., Lu, S., Feng, L., & Zhang, H. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03601-6 · Cited by 3
Biofilm mediated integrin activation and directing acceleration of colorectal cancer
Saravanan, V., Gopalakrishnan, V., Mahendran, M. I. M. S., Vaithianathan, R., Srinivasan, S., Boopathy, V., & Krishnamurthy, S. (2024) · Apmis · doi:10.1111/apm.13466 · Cited by 3
“For instance, in CRC, hyper-methylation of the MGMT gene’s promoter region is linked to chemotherapy resistance (165).”
Colorectal cancer chemoprevention: Exploring the path from molecular mechanisms to available drugs
Ivy, D. M., Bordone, R., Magno, L. D., Coni, S., & Canettieri, G. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189439 · Cited by 4
Epigenetics: Future prospective in human disorders and therapeutics
Rajpathak, S. N., Biradar, V. S., & Deobagkar, D. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00010-4 · Cited by 3
Zhang, H., Liang, Y., Deng, S., & Du, J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101851 · Cited by 2
“In cancer, abnormal methylation of specific genes, including gene silencing caused by promoter region methylation of tumor suppressor genes, has been shown to be closely associated with tumorigenesis, chemotherapy resistance, disease progression, and prognosis [40].”
Kang, M., Lee, E. S., Lee, E. S., Yu, H., Lee, T. G., Suh, Y. D., Na, H., Park, K., & Jahng, J. (2025) · Small Methods · doi:10.1002/smtd.202500919 · Cited by 2
Naz, S. S., & Ortega, J. S. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10745-6 · Cited by 1
“Emerging evidence suggests potential utility of demethylating agents in CIMP-H CRCs, warranting further investigation [34, 35].”
Rani, H., Subhadarshini, S., Jolly, M. K., & Mahadevan, V. (2025) · Epigenetics & Chromatin · doi:10.1186/s13072-025-00646-x · Cited by 1
“Methylation based therapies including AZA, DAC, SGI-110, or TMZ are currently in clinical trials for treatment of colorectal cancer patients [55].”
Utilising Proteomics and Organoid Cultures for Predicting Treatment Response in Colorectal Cancer
Micallef, I., & Baron, B. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106028 · Cited by 2
Türk, C. (2021) · Anatomy (International Journal of Experimental and Clinical Anatomy) · doi:10.2399/ana.21.852318
“Based on the fundamental role of DNA methylation in colon cancer development, the application of DNMT inhibitors for the treatment of colon cancer patients, especially patients with DNA hypermethylation, is recommended as a result of studies.([38]) Our results showed that the gene sets of Methyl transferase activity a…”
BackgroundEpigenetic Approach on Colorectal Cancer Systemic Therapy: Promising yet a Long Way to Go
Rezkitha, Y. A. A. (2022) · Gaceta Médica de Caracas · doi:10.47307/gmc.2022.130.2.14
Mazzocco, K., & Milani, A. (2023) · PNEI REVIEW · doi:10.3280/pnei2023-001005
Epigenetic modification: key regulator of reprogramming in cancer stem cells
Palol, V. V., Saravanan, S. K., Chinnadurai, R. K., & Subramanyam, V. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13212-4.00017-9
Ogurchyenok, N. E., Khalin, K. D., & Bryukhovetskiy, I. (2024) · Medicine International · doi:10.3892/mi.2024.149
“…disruption of DNa methylation is caused by mutations in DNa methyltransferase ( DNMT ) genes responsible for the genome‑wide methylation patterns (22); in particular, the methylation status of the promoter regions of the methylgua‑ nine‑DNa‑methyltransferase gene (23,24) he disruption of which…”
BackgroundXu, M., Ding, W., Pan, B., Yue, Y., Lin, K., Zhou, J., Chen, S., Pan, Y., Sun, L., & He, B. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4964507
Филиппова, Е. А., Сергеевна, Л. С., Loginov, V. I., Burdennyy, A. M., Валерьевна, П. И., Arzhanukhina, N. A., Kazubskaya, T. P., & Braga, E. A. (2024) · Russian Journal of Genetics · doi:10.1134/s1022795424700959
Filippova, E. A., Сергеевна, Л. С., Loginov, V. I., Burdennyy, A. M., Пронина, И. В., Arzhanukhina, N. A., Kazubskaya, T. P., & Braga, E. A. (2024) · Генетика · doi:10.31857/s0016675824100096
Li, Y., Shi, X. L., Ling, B., Su, X., & Jing, Z. (2025) · Biochemical Genetics · doi:10.1007/s10528-025-11307-9
“DNA methyltransferases catalyze this process, which generally leads to gene silencing and genomic instability, both of which contribute to an increased risk of tumor formation (Cervena et al. 2020; Hrasovec et al. 2013 ).”
Pang, S. W. (2024) · Sunway Institutional Repository (Sunway University)
Nakashidze, I., Petrović, N., Jahja, E., Nakashidze, I., & Barua, J. D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27765-8.00023-0
Osmani, N. E. (2022) · theses.fr (ABES) · doi:10.70675/44703178z2ad1z4ebcza891z61cf9febffe8 · Cited by 1
Hernández-Medina, F., Cornejo, A., & Orué, A. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1922606
“…instability (CIN), microsatellite instability (MSI), and CIMP pathways, growing evidence suggests substantial biological overlap among these mechanisms, highlighting the central role of epigenetic dysregulation in disease evolution (Dekker et al., 2019; Cervena et al., 2020; Bray et al., 2024).”
Metadata
- Authors
- Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V.
- Affiliations
- Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14 200 Prague, Czech Republic
- Charles University (CZ)
- Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59 Prague, Czech Republic
- Corresponding author
- Vymetalkova, Veronika
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-06-24
- Volume
- 9
- Issue
- 6
- Pages
- 1540
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7349319
- OpenAlex
- W3038126636
- Cited by
- 57
- References
- 241
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 16 · 2023: 7 · 2022: 11 · 2021: 5 · 2020: 4
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Grant Agency of the Ministry of Health of the Czech Republic (AZV 17-30920A and NV19-09-00237)
- Charles University Research Centre (UNCE/MED/006)
- Grant Agency of the Charles University (GAUK 302119)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colorectal cancer, DNA methylation, DNA methyltransferases, DNMT inhibitors, epigenetic therapy, DNA hypermethylation, chemoresistance, predictive biomarkers, molecular subtypes, epigenetic modifications
- MeSH terms
- Humans, Colorectal Neoplasms, DNA Methylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Figure 1 Consensus molecular subtypes (CMS) classification as proposed by Guinney et al. [131].](https://figures.cochat.ai/paper-figures/963c902904204d22894d0af4c77fd8c1/methylation-based-therapies-for-colorectal-cancer-figure-1.jpg)
